Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

The registered record

Accession number

NCT05417308

Lead sponsor

Ohio State University Comprehensive Cancer Center (other)

Registered condition naming hair loss

Endocrine Therapy-Induced Alopecia

Also registered on this record

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8

Official title

A Pilot Trial of Topical vs Oral Minoxidil for Treatment of Endocrine Therapy-Induced Alopecia in Breast Cancer Patients

The first row holds the registered condition that placed this trial on the pipeline; the second holds everything else the sponsor registered on the same record. Both are shown, and shown apart rather than shaded differently, because leaving the second out would make this trial look more like a hair-loss study than its registration says it is — and because a distinction carried only by colour is not a distinction for every reader.

Interventions

• DrugMinoxidil
• DrugMinoxidil
• OtherQuality-of-Life Assessment
• OtherQuestionnaire Administration

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type

interventional

Phase

Early Phase 1

Allocation

randomized

Masking

double

Primary purpose

treatment

Enrolment

50 participants (estimated)

Sites

1 location in United States

What it measures

1. Proportion of days assigned medication was taken/applied

   Time frame: Up to 12 months

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex

female

Age

18 Years

Healthy volunteers

not accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start

1 March 2023 (actual)

Primary completion

1 December 2027 (estimated)

Study completion

31 December 2027 (estimated)

First posted

14 June 2022 (actual)

Last update posted

10 March 2026 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: this record registers a primary completion to the day, so a day is what is shown. Where a sponsor registers only a month, only a month is shown.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Chemotherapy Hair Loss: Which Drugs Cause It, What Scalp Cooling Achieves, and the Regrowth Timeline

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT05417308 on ClinicalTrials.gov · All 157 trials in the pipeline